| Literature DB >> 26884758 |
Shivangi Goyal1, Nidhi Gupta1, Sreemoyee Chatterjee1.
Abstract
Current lifestyle, stress, and pollution have dramatically enhanced the progression of several diseases in human. Globally, scientists are looking for therapeutic agents that can either cure or delay the onset of diseases. Medicinal plants from time immemorial have been used frequently in therapeutics. Of many such plants, fenugreek is one of the oldest herbs which have been identified as an important medicinal plant by the researchers around the world. It is potentially beneficial in a number of diseases such as diabetes, hypercholesterolemia, and inflammation and probably in several kinds of cancers. It has industrial applications such as synthesis of steroidal hormones. Its medicinal properties and their role in clinical domain can be attributed to its chemical constituents. The 3 major chemical constituents which have been identified as responsible for principle health effects are galactomannan, 4-OH isoleucine, and steroidal saponin. Numerous experiments have been carried out in vivo and in vitro for beneficial effects of both the crude chemical and of its active constituent. Due to its role in health care, the functional food industry has referred to it as a potential nutraceutical. This paper is about various medicinal benefits of fenugreek and its potential application as therapeutic agent against several diseases.Entities:
Year: 2016 PMID: 26884758 PMCID: PMC4739449 DOI: 10.1155/2016/1250387
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
Figure 1Herbal product as phytopharmaceutical: steps involved in the process of drug development.
| Activity | Dose | Content | Mode of application | Vehicle | Parameters | Reference |
|---|---|---|---|---|---|---|
| Anticancer | 200 mg/kg b.wt | Flavonoids | — | Aqueous and olive oil | Inhibition of the mammary hyperplasia | [ |
| 100 mg/kg and 200 mg/kg b.wt | — | Intraperi- | Ethanolic | Alterations of ascites cells | [ | |
| 25–800 mg/kg b.wt | Saponins, flavonoids, alkaloids, and galactomannans | Oral | Methanol | General: tumor incidence; biochemical: liver GSH and LPO | [ | |
| 2 g/kg b.wt | Saponins, flavonoids, and fiber | Oral | — | Inhibition of colon carcinogenesis by modulating glucuronidase and mucinase activity | [ | |
|
| ||||||
| Antidiabetic | 0.44–1.74 g/kg·d | — | Oral | Aqueous | Reduction in blood glucose and improvement of hemorheological properties | [ |
| 50 mg/kg b.wt and 100 mg/kg b.wt | — | Oral | Water | Decrease in blood glucose | [ | |
| 0.5 g/kg b.wt | — | Oral | Alcoholic | Reduction of blood glucose level | [ | |
| 1 g/kg b.wt | — | Oral | Aqueous and methanolic | Hypoglycemic effect | [ | |
|
| ||||||
| Anticholesterol/ | 0.44–1.74 g/kg·d | — | Oral | Aqueous | Reduction in blood lipid levels | [ |
| 100 mg/kg b.wt | — | Oral | Water | Decrease in serum lipids | [ | |
| 0.5 g/kg | — | — | — | Decrease in triglycerides and total cholesterol | [ | |
| 30 or 50 g ethanol extract/kg b.wt | Saponins | Oral | Ethanol | Reductions in plasma cholesterol levels | [ | |
|
| ||||||
| Anti-inflammatory | 50–200 mg/kg b.wt | — | — | Aqueous | Stimulatory effect on immune system | [ |
| 150 mg/kg b.wt | — | — | Ethanolic | Effective against acute and chronic inflammation | [ | |
|
| ||||||
| Antioxidant | 0.4 g/kg b.wt | — | Oral | — | Reduction in the level of serum MDA | [ |
| 0.11 g/kg b.wt | — | — | — | Decrease in SOD activity | [ | |
| 0.4 g/kg b.wt | Flavonoids and polyphenols | Oral | Aqueous | Decrease in the level of MDA | [ | |
|
| ||||||
| Antimicrobial | Flavonoids | Aqueous | Inhibition of | [ | ||
| Aqueous, methanolic, and ethanolic | Methanolic and ethanolic extracts were effective against | [ | ||||
| Activity | Dose | Constituent | Vehicle | Parameters | Reference |
|---|---|---|---|---|---|
| Antioxidant | 20–100 | Polyphenols | Methanol | Scavenging hydroxyl radical, DPPH, abts, changes in LPO, SOD, and inhibition of H2O2 induced lipid peroxidation | [ |
| 25–200 mg/mL | Flavonoids and alkaloids | Ethanolic | Scavenging DPPH and inhibition of lipid peroxidation | [ | |
|
| |||||
| Anticancer | Induction of apoptosis in HT-29 human colon cancer cells | [ | |||
| Diosgenin | Inhibition of cell proliferation in the human osteosarcoma 1547 cell line | [ | |||
| Diosgenin | Chloroform | Killed MCF-7 human immortalized breast cells | [ | ||
| Ethanolic | Cytotoxic to breast cancer cell line and prostate cancer cell line | ||||
|
| |||||
| Antidiabetic | 0.33 and/or 3.3 mg/mL | Saponin, sapogenin, diosgenin, and trigonelline | Ethanolic | Inhibition of glucose uptake | [ |
| 1 gm/day | 4-Hydroxyisoleucine | Hydro- | Direct pancreatic | [ | |
| 5–20 mM | — | Aqueous | Reduction in | [ | |
|
| |||||
| Anti-inflammatory | Saponin | Methanolic | Inhibition of TNF- | [ | |
| Steroidal saponin | Aqueous | Peroxyl radical scavenging effects and reduction of release of ROS from inflamed mucosa | [ | ||
|
| |||||
| Antimicrobial | 16–128 mg/mL | Essential oil | Methanolic and acetone | Antimicrobial activity against | [ |
| 100 mg | Defensin | Inhibits the mycelial spread of | [ | ||